PCSK9 and familial hypercholesterolemia: Of concern, in a 2021 trial, two young patients with pure-sibling familial hypercholesterolemia (12 years old and 16 years old) experienced almost complete regression of plaque after intensive lipid-lowering with PCSK9 inhibitors in combination with other lipid-lowering agents (Reeskamp et al., 2021).